Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation

Dec 18 2019

• By Cathy Kelly

Syringe

Related Content

CREATES Act Approaches Finish Line But Legislation May Fail To Launch

Jul 08 2019

Mylan/Biocon Running Out Of Time To Get Insulin Approved Before US Transition

Sep 05 2019

USMCA Trade Negotiations: Could US House Dems' Talks Open Door For AAM Changes?

Jun 26 2019

A Guide To US FDA’s Drug-To-Biologic Transition Process

May 09 2019

US FDA Moves To Codify Size-Based Threshold For Drugs To Be Deemed Biologics

Dec 12 2018

Related Companies

Sanofi

Viatris Inc.

Biocon, Ltd.

Additional Topics

United States Legislation Generic Drugs Biosimilars Biologics FDA Pricing Debate BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.